Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fusion AntibodiesLSE:FAB 26 Debt-to-Equity is 0.53 as of Sep. 2025, which is 1667% above its 10-year median of 0.03. GuruFocus rates LSE:FAB with a GF Score™ of 26/100 and a GF Value™ of £0.04 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 959 Biotechnology companies, Fusion Antibodies ranks worse than 76.75% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Fusion Antibodies's Debt-to-Equity or its related term are showing as below:
LSE:FAB'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.03 Max: 0.53
Current: 0.53
During the past 11 years, the highest Debt-to-Equity Ratio of Fusion Antibodies was 0.53. The lowest was 0.01. And the median was 0.03.
LSE:FAB's Debt-to-Equity is ranked worse than 76.75% of 959
companies
in the Biotechnology industry
Industry Median: 0.15
vs LSE:FAB: 0.53
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Fusion Antibodies Debt-to-Equity Related Terms
Fusion Antibodies Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Fusion Antibodies's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:FAB vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Fusion Antibodies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fusion Antibodies Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fusion Antibodies's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Fusion Antibodies's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fusion Antibodies (LSE:FAB) has a Debt-to-Equity of 0.53 as of Sep. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Fusion Antibodies and its competitors. This is 1667% above median its historical median of 0.03. Over the past decade, Fusion Antibodies' Debt-to-Equity has ranged from 0.01 to 0.53. According to the industry distribution chart, Fusion Antibodies ranks #736 out of 959 companies in the Biotechnology industry, placing it in the top 76.7%.
Is Fusion Antibodies' Debt-to-Equity too high?
Fusion Antibodies' current Debt-to-Equity of 0.53 is 1667% above median its 10-year median of 0.03. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.53. The Biotechnology industry median Debt-to-Equity is 0.15. Fusion Antibodies' value of 0.53 is 253.3% above this industry median. Based on the distribution chart, Fusion Antibodies ranks #736 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Fusion Antibodies has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fusion Antibodies' Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fusion Antibodies ranks #736 out of 959 companies for Debt-to-Equity. This places Fusion Antibodies in the lower half of its industry. The industry median Debt-to-Equity is 0.15. Fusion Antibodies' value of 0.53 is 253.3% above this benchmark. Historically, Fusion Antibodies' own Debt-to-Equity has ranged from 0.01 to 0.53 over the past decade. While the company's 10-year median is 0.03 vs. the industry median of 0.15, Fusion Antibodies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.15, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fusion Antibodies's current Debt-to-Equity of 0.53 is 253.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Fusion Antibodies and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fusion Antibodies's current Debt-to-Equity is 0.53, which is 1667% above median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fusion Antibodies stock overvalued right now?
Based on GuruFocus' analysis, Fusion Antibodies (LSE:FAB) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.04, compared to a current price of £0.10 — trading 156.3% above its estimated fair value. The current Debt-to-Equity is 0.53, which is 1667% above median its 10-year median of 0.03 and 253.3% above the Biotechnology industry median of 0.15. Fusion Antibodies' overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Fusion Antibodies (LSE:FAB), the current Debt-to-Equity is 0.53 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fusion Antibodies (LSE:FAB) Overvalued in 2026?
Based on GuruFocus' analysis, Fusion Antibodies stock appears to be overvalued.
The current stock price of £0.10 is trading 156.3% above its estimated GF Value™ of £0.04.
GuruFocus considers Fusion Antibodies to be Significantly Overvalued.
Key valuation signals for LSE:FAB:
Debt-to-Equity: 0.53 (1667% above median its 10-year median of 0.03)
GF Value™: £0.04 vs. price of £0.10 (156.3% above fair value)
Industry Position: 253.3% above the Biotechnology median (#736 of 959)
No single metric tells the full story. See the LSE:FAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fusion Antibodies PLC is a Contract Research Organisation (CRO) providing antibody identification, engineering, and expression services for the discovery and development of antibodies for human and veterinary therapeutics, as well as for diagnostics. Its customers are pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company's three core service areas include: Discovery (identification, screening, and sequencing of novel antibodies); Engineering (optimising the performance of antibodies); and Supply (production and purification of antibodies for further development). Geographically company generates the majority of its revenue from North America and the Rest of the World, followed by the United Kingdom and the Rest of Europe.
26GF Score
Get the complete analysis for LSE:FAB
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:FAB has been successfully added to your 
